CJC-1295 DAC: Risks & Legal Status

Risk Assessment#

CJC-1295 DAC presents a mixed risk profile. The short-term clinical trial data suggest a favorable safety profile at the doses and durations studied. However, the compound raises significant theoretical concerns related to the long-term consequences of sustained GH and IGF-1 elevation, the lack of long-term safety data, and the irreversible nature of its prolonged pharmacological effect.

Primary Risks#

Investigational Status and Limited Data#

CJC-1295 DAC has completed only Phase 1 and Phase 2 clinical studies with small sample sizes and limited treatment durations (up to 8 weeks). The clinical development program was discontinued before Phase 3 trials, meaning that the compound has not undergone the rigorous large-scale safety and efficacy evaluation required for regulatory approval.

The available clinical data are sufficient to characterize the acute pharmacological effects and short-term safety profile but are inadequate for assessing the risks of chronic use. Important safety questions, including the effects on body composition, cardiovascular health, cancer risk, and metabolic parameters with prolonged use, remain unanswered.

Cancer Risk from IGF-1 Elevation#

The relationship between IGF-1 and cancer risk represents the most significant theoretical concern for any compound that chronically elevates IGF-1 levels. Multiple large epidemiological studies have demonstrated positive associations between higher circulating IGF-1 concentrations and increased risk of colorectal cancer, prostate cancer, and pre-menopausal breast cancer.

While these associations do not prove causation, the biological plausibility is strong: IGF-1 is a potent mitogenic and anti-apoptotic factor that promotes cell proliferation and inhibits programmed cell death. Elevated IGF-1 could theoretically promote the growth of existing precancerous or cancerous cells.

CJC-1295 DAC produces sustained IGF-1 elevation of 1.5 to 3 times above baseline with weekly dosing. The clinical significance of this elevation for cancer risk is unknown, as the epidemiological studies examined endogenous IGF-1 variation rather than pharmacologically induced elevation. Nevertheless, CJC-1295 DAC should be considered absolutely contraindicated in individuals with active malignancy or a significant cancer history.

Metabolic Effects#

Growth hormone has counter-regulatory effects on insulin action, promoting lipolysis and hepatic gluconeogenesis while reducing peripheral glucose uptake. Chronic GH elevation can lead to insulin resistance and impaired glucose tolerance, potentially precipitating type 2 diabetes in susceptible individuals.

In the short-term clinical trials of CJC-1295 DAC, no significant changes in glucose or insulin parameters were observed. However, the study durations were too short to detect the gradual metabolic effects that would be expected with chronic use. Monitoring of fasting glucose and hemoglobin A1c is recommended for anyone using CJC-1295 DAC over extended periods.

Long Half-Life and Irreversibility#

The 6 to 8 day half-life of CJC-1295 DAC, while advantageous for dosing convenience, represents a safety liability. If adverse effects develop, the pharmacological action cannot be rapidly terminated. After discontinuation of CJC-1295 DAC, significant GH and IGF-1 elevation persists for 1 to 2 weeks as the albumin-conjugated peptide is slowly cleared from the circulation.

This contrasts with shorter-acting GHRH analogs (such as CJC-1295 without DAC or sermorelin) where the pharmacological effects resolve within hours of the last dose. The long half-life also means that cumulative accumulation occurs with weekly dosing, with steady-state levels approximately 2 to 3 times higher than after a single dose.

Regulatory and Legal Status#

CJC-1295 DAC is not approved for human use by any regulatory agency worldwide. In the United States, it is available as a research chemical but cannot be legally marketed or sold for human use. The regulatory status varies internationally, with Australia classifying it as a Schedule 4 prescription-only medicine with restricted importation.

CJC-1295 DAC is explicitly prohibited by the World Anti-Doping Agency (WADA) under the category of growth hormone secretagogues (Section S2.3 of the Prohibited List). Athletes subject to anti-doping testing who use CJC-1295 DAC face sanctions including disqualification and suspension.

Quality and Sourcing Risks#

CJC-1295 DAC available through research peptide suppliers is not manufactured under pharmaceutical GMP conditions. Quality concerns include peptide purity, correct sequence identity, and most critically, the integrity and reactivity of the DAC moiety. If the maleimide group in the DAC has undergone hydrolysis during storage or handling, the peptide will not effectively bind albumin and will lack the extended half-life that is its defining pharmacological feature. This would result in a pharmacological profile more similar to CJC-1295 without DAC than to the intended long-acting formulation.

Risk-Benefit Assessment#

For healthy individuals, the risk-benefit assessment of CJC-1295 DAC is unfavorable from a medical perspective. The potential benefits of GH axis stimulation (improved body composition, recovery, anti-aging effects) are supported only by indirect evidence from the GH replacement therapy literature, not by clinical trials of CJC-1295 DAC itself. The risks, while largely theoretical for short-term use, include meaningful concerns about metabolic effects and cancer risk with chronic use.

The compound may have a more favorable risk-benefit profile in specific clinical contexts, such as adult GH deficiency, where the therapeutic need is established and the alternative (daily GH injections) is more burdensome. However, these applications would need to be evaluated in properly designed clinical trials.

Recommendations#

For researchers and clinicians considering CJC-1295 DAC: use only analytically verified material from reputable sources; do not use in individuals with active malignancy, cancer history, or uncontrolled diabetes; monitor IGF-1 levels to ensure they remain within physiological ranges; monitor glucose metabolism parameters during use; use the lowest effective dose and shortest duration consistent with the research objectives; and recognize that the long half-life prevents rapid reversal of pharmacological effects.

Related Reading#

• CJC-1295 DAC overview and research guide
• CJC-1295 DAC side effects profile
• CJC-1295 DAC research evidence